Attendee search 

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Bioversys AG is a privately held Swiss biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch-off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, we have profound technological expertise that is based on solid IP.

Biovotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive physiological monitoring. The Biovotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable monitor of vital sign parameters, supported by integrated cloud services for data exchange and analysis. It is directed towards patients with chronic conditions featuring Biovotion’s patient-friendly, wearable monitoring concept.

The company holds internationally recognised know how, paired with an extensive IP portfolio in a number of fields, relevant to provide sensor technology and device development for continuous and non-invasive physiological monitoring, embedded into mHealth environments.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Sanifit offers a new approach for calcification disorders. Sanifit´s lead Product (SNF472) for the reduction of calcification in dialysis patients is entering Phase I clinical trials. For the dental field OTC products were developed and are being out-licensed. The international management team has proven track record and long industry experience. Sanifit operates from Switzerland and Spain

Founded in 2001 and located in Zurich, Aravis is the first independent Swiss on-shore private equity house. With a track record of investment in the renewable energy and life science spaces, Aravis is currently managing more than a quarter of a billion Swiss francs.

With a long track record in life sciences and two life science investment funds (ARAVIS Biotech I and ARAVIS Biotech II), Aravis has held an early stage stake in some of the more eye-catching Swiss life science companies and has had over the years some notable exits through reverse takeover,  IPO or acquisition.

Aravis has a distinct and crafted approach to investment, taking a “hands on” approach that balances between finance, commercial assets and people. This approach transcends industry sector and with years of collected experience and expertise, Aravis has established a comprehensive investment platform that also incorporates accounting, regulatory and reporting expertise specific to Switzerland but also more widely. This means that Aravis is well placed to manage external funds for clients and institutions as well as putting together further internal funds focused on current and new industry sectors

Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is financially supported by an investment by EVA- a Basel based venture capital company- and uses a network of strategic partners to develop the production of EGF and develop a suitable cream-based pharmaceutical product. Producers for the cGMP production of high-quality EGF(epidermal growth factor) and for a stable cream formulation of the active ingredient have been contracted and a Proof-of-Concept trial is running at the Dermatology Clinic of the University of Zurich. The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and test an optimised formulation for clinical efficacy and safety. Results of the trial are expected in Q1 2013.

Headquartered in Geneva, Switzerland, NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class pre-clinical and clinical drug candidates with a mix of both clinically validated and novel targets.

§  CHF 182M raised from high net worth individuals, private and corporate venture funds

§  In 2009, received the European Biotechnica Award

§  In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate

§  In 2011, received Orphan Drug designation in Europe and the USA for, and EUR 6 million FP7 grant from the European Commission for development of NI-0501 for HLH

§  In 2012, filing to initiate important clinical studies including the first Phase II study for NI-0501 in HLH, and first-in-man study for leading anti-TLR4 drug candidate, NI-0101

§  Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates

§  Potential to independently bring selected drugs to the market for focused applications

Bioversys AG is a privately held Swiss biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch-off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, we have profound technological expertise that is based on solid IP.